Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine

被引：2

作者：

Hubner, R. ^{[1
]}

Cubillo, A. ^{[2
]}

Blanc, J. -F. ^{[3
]}

Melisi, D. ^{[4
]}

Von Hoff, D. ^{[5
]}

Wang-Gillam, A. ^{[6
]}

Chen, L. -T. ^{[7
]}

Becker, C. ^{[8
]}

Mamlouk, K. ^{[8
]}

Belanger, B. ^{[8
]}

Yang, Y. ^{[9
]}

De Jong, F. ^{[10
]}

Siveke, J. ^{[11
]}

机构：

[1] Christie NHS Fdn Trust, Manchester, Lancs, England

[2] Hosp Univ HM Madrid Sanchinarro, Madrid, Spain

[3] Hop St Andre, Bordeaux, France

[4] Univ Verona, Med Oncol, Verona, Italy

[5] TGen & HonorHlth, Phoenix, AZ USA

[6] Washington Univ, St Louis, MO USA

[7] Natl Inst Canc Res, NHRI, Tainan, Taiwan

[8] Merrimack Pharmaceut Inc, Cambridge, MA USA

[9] Baxalta Inc, Cambridge, MA USA

[10] Baxalta, Opfikon, Switzerland

[11] Univ Hosp Essen, West German Canc Ctr, Essen, Germany

来源：

关键词：

D O I：

10.1093/annonc/mdw198.04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O-004

引用

页码：119 / 119

页数：1